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Abstract
Prokineticin-1 (PK1) is a recently described protein with a wide range of functions, including
tissue-specific angiogenesis, modulation of inflammatory responses, and regulation of
hemopoiesis. The aim of this study was to investigate the localization and expression of PK1 and
PK receptor-1 (PKR1), their signaling pathways, and the effect of PK1 on expression of the
inflammatory mediators cyclooxygenase (COX)-2 and IL-8 in third-trimester placenta. PK1 and
PKR1 were highly expressed in term placenta and immunolocalized to syncytiotrophoblasts,
cytotrophoblasts, fetal endothelium, and macrophages. PK1 induced a time-dependent increase in
expression of IL-8 and COX-2, which was significantly reduced by inhibitors of Gq, cSrc,
epidermal growth factor receptor (EGFR), and MAPK kinase. Treatment of third-trimester
placenta with 40 nM PK1 induced a rapid phosphorylation of cSrc, EGFR, and ERK1/2.
Phosphorylation of ERK1/2 in response to PK1 was dependent on sequential phosphorylation of
cSrc and EGFR. Using double-immunofluorescent immunohistochemistry, PKR1 colocalized with
IL-8 and COX-2 in placenta. These data suggest that PK1 may have a novel role as a mediator of
the inflammatory response in placenta.
Prokineticin-1 (PK1) [also known as endocrine gland-derived vascular endothelial growth
factor (VEGF)] is a recently described protein with a range of physiological and
pathological functions (1). The cognate receptors for PK1 are two closely related G protein-
coupled receptors, PK receptor (PKR)-1 and PKR2. These couple to either Gi or Gq (2-4),
activating downstream signaling pathways that include calcium mobilization, stimulation of
phosphoinositide turnover, and activation of MAPK.
PK1 is expressed in steroidogenic tissues including the placenta (5, 6), ovary (7, 8), and
adrenal (3). It mediates tissue-specific vascular effects, which include capillary endothelial
cell survival, proliferation, differentiation, and induction of fenestrae (3). In contrast to
VEGF, PK1 has no effect on endothelial cells derived from aorta, umbilical vein, or cornea
(5). More recently, mouse studies have demonstrated that PKR1 gene activation promotes
angiogenesis in cultured cardiac endothelial cells without increasing VEGF levels (9). PK1
is also thought to have a role in immune regulation, affecting differentiation of human bone
marrow cells into a distinct monocyte-derived cell population primed for release of
proinflammatory cytokines (10). On stimulation with LPS, PK1-primed monocytes/
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macrophages demonstrate an exaggerated release of IL-12 and TNF-α and down-regulated
production of IL-10 (10), thus favoring a proinflammatory T-helper cell type 1 response.
During the first trimester of pregnancy, PK1 and PKR1 are predominantly expressed in
syncytiotrophoblast, with expression peaking from 8–10 wk gestation. PK1 is also expressed
in specialized macrophages called Hofbauer cells in the placental villi from 6 wk of
gestation. In contrast, PK2 is not expressed in trophoblast and expression of PKR2 is 80
times less than that of PKR1 (6). Supported by studies in the mouse (11), it has therefore
been suggested that PK1 may have a role in trophoblast differentiation and placental
angiogenesis during early pregnancy. Less is known about placental expression of PK1 and
PKR1 in later pregnancy. Although PK1 expression has been demonstrated in normal third-
trimester placenta, its immunolocalization and putative functions are not known (12).
Moreover, the expression and immunolocalization of PKR1 in third-trimester placenta
remain to be investigated.
We have recently found that PK1 induces up-regulation of IL-8 and cyclooxygenase
(COX)-2 in a PKR1-overexpressing human endometrial epithelial cell line (13). Both IL-8
and COX-2 are important inflammatory and vascular mediators. IL-8 is a potent neutrophil
chemoattractant and angiogenic factor, promoting endothelial cell chemotaxis (14), whereas
COX-2 is the inducible isoform of the enzyme involved in the synthesis of prostaglandins
from arachidonic acid (15). We therefore postulated that PK1 may, via stimulation of IL-8
and COX-2, be a novel mediator of the inflammatory response in term placenta.
The current study therefore had two objectives: first, to investigate the expression,
localization, and signaling pathways of PK1 and PKR1 in third-trimester human placenta,
and second, to study the effect of PK1 on the expression of IL-8 and COX-2.
Materials and Methods
Patients and tissue collection
Placentae (n = 32) and myometrium (full-thickness biopsy from lower uterine segment; n =
13) were collected at elective cesarean section (>37 wk gestation, uncomplicated singleton
pregnancy). Nonpregnant myometrium (n = 6) was obtained from the uterine muscle layer
distant from any pathology in women undergoing hysterectomy for uterine fibroids. Shortly
after collection, tissue was placed in RNAlater (Applied Biosystems, Warrington, UK) for
RNA extraction, fixed in 4% neutral buffered formalin, and wax embedded for
immunohistochemistry or placed in RPMI (Sigma, Poole, UK) (containing 2 mM L-glutamine,
100 IU penicillin, and 100 μg/ml streptomycin) and transported to the laboratory for in vitro
culture. Ethical approval was obtained from Lothian Local Research Ethics Committee,
written informed consent was obtained from all subjects before tissue collection, and the
study was conducted in accordance with the guidelines provided in The Declaration of
Helsinki.
Immunohistochemistry
PK1 and PKR1 were localized by immunohistochemistry as previously described (16, 17).
Briefly, 5-μm placental sections were dewaxed in xylene and rehydrated in graded ethanol.
Antigen retrieval was performed by treating sections for 5 min in a pressure cooker in
boiling 0.01 M citrate buffer (pH 6.0). Endogenous peroxidase activity was quenched with
10% (vol/vol) H2O2 in methanol at room temperature. Nonimmune swine serum (20%
serum in Tris-buffered saline) was applied for 30 min before overnight incubation at 4 C
with rabbit antihuman PK1 (1:1000; Phoenix Pharmaceuticals Inc., Belmont, CA) or rabbit
antihuman PKR1 (1:500; Caltag Medsystems, Botolph Claydon, UK). An avidin-biotin
peroxidase detection system was then applied (Dako Ltd., Cambridge, UK) with 3,3′-
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diaminobenzidine as the chromogen. Controls were incubated with isotype-matched IgG in
place of primary antibody.
Confocal immunofluorescence microscopy
Colocalization of PKR1 with cytokeratin-18 (trophoblast marker), CD31 (blood vessel
marker), CD68 (macrophage marker), CD3 (T-cell marker), CD20 (B-cell marker), IL-8,
and COX-2 was performed by dual-immunofluorescence histochemistry. Sections were
prepared and blocked in 5% normal chicken serum before incubating overnight at 4 C with
antibodies directed against cytokeratin 18 (1:20), CD31 (1:100), CD3 (1:10), COX-2 (1:50;
all Autogen Bioclear, Wiltshire, UK), CD68 (1:10), CD20 (1:20; both Dako), and IL-8
(1:10; R&D Systems Europe Ltd., Abingdon, UK). Subsequently, sections were incubated in
appropriate biotinylated chicken secondary antibodies (1:200; all Autogen Bioclear),
followed by incubation with the fluorochrome Avidin 488 Alexafluor (1:200 in PBS;
Invitrogen, Paisley, UK). Sections were reblocked with 5% normal chicken serum and then
incubated overnight at 4 C with rabbit antihuman PKR1 (1:500; Caltag Medsystems).
Control sections were incubated with rabbit IgG. Finally, sections were washed, incubated
for 10 min in TyrCy3 Red (1:50 in substrate; PE Healthcare, Amersham, UK), incubated
with the nuclear counterstain To-Pro 2 (1:1000; Invitrogen) and mounted in Permafluor
(Beckman Coulter, High Wycombe, UK). Sections were visualized and photographed using
a laser-scanning microscope (LSM 510; Carl Zeiss, Jena, Germany) using a ×40 1.4 oil
immersion lens. Control sections were incubated with normal IgG from the same host
species.
Cell signaling experiments
To investigate PKR1 signaling pathways in placenta, after washing in PBS, finely chopped
(2–3 mm) placental tissue was incubated overnight at 37 C in serum-free medium [DMEM/
F-12 medium with L-glutamine (Invitrogen) containing 100 IU penicillin and 100 μg/ml
streptomycin (PAA Laboratories, Middlesex, UK)]. Tissue explants were then incubated for
0, 5, 10, 20, and 30 min in the presence of 40 nM PK1 (Peprotech, London, UK), snap frozen
in dry ice, and stored at −80 C for protein analysis. To dissect the signaling pathways
further, after overnight incubation, tissue was preincubated for 1 h with vehicle or inhibitors
of Gq (YM-254890, 1 μM), cSrc (PP2, 10 μM), epidermal growth factor receptor (EGFR)
kinase (AG1478, 200 nM) or MAPK kinase (MEK) (PD98059, 50 μM; all obtained from
Merck Chemicals, Nottingham, UK, except YM-254890 a kind gift from M. Taniguchi,
Astellas Pharmaceuticals Inc., Tokyo, Japan) and then treated for 30 min with vehicle or 40
nM PK1. Doses of chemical inhibitors were determined empirically by titration. The IC50
values for inhibition of MEK with PD98059 is 50 μM (18). At this concentration, it is not
known to inhibit other serine/threonine kinases. AG1478 is reported to be a selective
inhibitor of EGFR kinase, used in the present study at 200 nM, well below the IC50 for
inhibition of HER2-neu (IC50 > 100 μM) and platelet-derived growth factor receptor kinase
(IC50 > 100 μM) (19). PP2 is a potent inhibitor of the c-Src family of nonreceptor tyrosine
kinases, used at 10 μM, well below the IC50 values for inhibition of JAK2/ZAP-70 pathway
(IC50 > 50 μM) (20). After treatment, tissue was frozen and stored until use. Frozen tissue
fragments were lysed and proteins extracted in 750 μl lysis buffer [150 mM NaCl, 50 mM
Tris-HCl (pH 7.4), 10 mM EDTA, 0.6% Nonidet-P40 substitute, and 10% glycerol containing
protease inhibitors] in a tissue lyser (QIAGEN, Crawley, UK) and centrifuged for 20 min at
19,000 × g. Proteins were quantified by the method of Lowry (Bio-Rad, Hemel Hempstead,
UK).
Western blot analysis
To investigate phosphorylation of ERK1/2, proteins (20–40 μg) were resolved on 4–12%
Bis-Tris gels (Nupage; Invitrogen) and transferred onto polyvinylidene difluoride membrane
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(Millipore, Watford, UK). Membranes were blocked for 1 h at 25 C in Odyssey blocking
buffer (Li-Cor Bioscience, Cambridge, UK) and incubated overnight at 4 C in blocking
buffer containing rabbit anti-phospho-p42/44 ERK and mouse anti-p42 ERK (both obtained
from Cell Signaling Technologies, New England Biolabs, Hertfordshire, UK; 1:1000). After
washing in PBS containing 0.05% vol/vol Tween, membranes were incubated for 1 h at 25
C in the dark in antimouse IgG conjugated to IRDYE 800 (Tebu-bio, Peterborough, UK)
and antirabbit IgG conjugated to Alexa Fluor 680 (Invitrogen) both at a dilution of 1:5000 in
blocking buffer. Membranes were washed and proteins visualized and quantified using an
Odyssey Infrared Imaging System (Li-Cor Bioscience). Relative density of immunoblots
was calculated as phosphorylated ERK divided by the total ERK and was expressed as a fold
change above vehicle controls.
For immunoprecipitation, equal amounts of protein were incubated overnight at 4 C with
gentle rotation with an anti-phosphotyrosine antibody conjugated to agarose beads (20 μg
for 1–2 mg protein; Autogen Bioclear, Wiltshire, UK). Beads were washed extensively with
lysis buffer, and immune complexes were solubilized in Laemmli buffer [125 mM Tris-HCl
(pH 6.8), 4% SDS, 5% 2-mercaptoethanol, 20% glycerol, and 0.05% bromophenol blue] and
subjected to Western blotting with antibodies to phospho-EGFR (Autogen Bioclear) or
phospho-cSrc (Merck Chemicals; both 1:1000 in blocking buffer). Membranes were
incubated for 1 h in the dark in appropriate antibodies conjugated to Alexa Fluor 680
(1:5000 in blocking buffer; Invitrogen), and proteins were visualized by the Odyssey system
as above. Relative densities of immunoblots were calculated as for phosphorylated ERK.
The signal levels were normalized to light-chain IgG.
COX-2 and IL-8 gene expression experiments
To investigate the effect of PK1 on expression of COX-2 and IL-8, placental explants were
preincubated in serum-free medium overnight, as for cell signaling experiments, and were
then incubated for 2, 4, 6, 8, and 24 h in serum-free medium containing vehicle or 40 nM
PK1. At the end of experiments, tissue was snap frozen in dry ice and stored at −80 C until
subsequent RNA extraction. To investigate the role of the Gq, cSrc, EGFR, and ERK
pathway in PK1-mediated expression of COX-2 and IL-8, tissue was serum starved
overnight and then preincubated for 1 h with vehicle or inhibitors of Gq (YM-254890, 1 μM),
cSrc (PP2, 10 μM), EGFR kinase (AG1478, 200 nM), or MEK (PD98059, 50 μM). After pre-
treatment, tissue samples were divided into two and treated for 4 h with the same chemical
inhibitors in the presence of either vehicle or 40 nM PK1. Tissue was then stored until
subsequent RNA extraction. Although no direct measure of tissue integrity after culture was
conducted in our studies (21), we measured RNA integrity as an indirect indicator of tissue
viability using the Agilent system. In all our samples, the RNA integrity at the end of culture
was comparable to that extracted from tissue shortly after collection. Moreover, there was no
difference in RNA quality in samples subjected to the various treatment groups.
TaqMan quantitative RT-PCR
After treatment, tissue samples were disrupted using a tissue lyser (QIAGEN, Crawley, UK)
in total RNA isolation reagent (TRIR; ABgene, Epsom, UK) or RNA lysis buffer (RNeasy
system; QIAGEN). RNA samples were then extracted according to the manufacturer's
instructions using phase-lock tubes (Eppendorf, Cambridge, UK). RNA samples were
quantified and reverse transcribed as described previously (17). Quantitative PCR was
performed using 2 μl cDNA in 50 μl of reaction mix containing 25 μl Master Mix (Applied
Biosystems, Warrington, UK), forward and reverse primers, and FAM/TAMRA-labeled
probe, together with VIC/TAMRA-labeled internal control reagents (ribosomal 18S). The
sequences of primers and probes were as follows: IL-8, forward 5′-
CTGGCCGTGGCTCTCTT-3′, reverse 5′-TTAGCACTCCTTGGCAAAACTG-3′, and
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probe 5′-FAM-CCTTCCTGATTTCTGCAGCTCTGTGTGAA-TAMRA-3′; COX-2,
forward 5′-CCT TCCTCCTGTGCCTGATG-3′, reverse 5′-
ACAATCTCATTTGAATCAGGAAGCT-3′, and probe 5′-FAM-
TGCCCGACTCCCTTGGGTGTCATAMRA-3′; 18S, forward 5′-
CGGCTACCACATCCAAGGAA-3′, reverse 5′-GCTGGAATTACCGCCTGCT-3′, and
TAMRA probe 5′-VICTGCTGGCACCAGACTTGCCCTC-TAMRA-3′. PCRs were
carried out using an ABI 7900HT (Applied Biosystems). Gene expression was normalized to
RNA loading using ribosomal 18S as an internal standard. Results are expressed as relative
to a positive RNA standard (cDNA obtained from single endometrial tissue) included in all
reactions.
Statistics
All data are expressed as mean ± sem. Where appropriate, results were subjected to
statistical analysis by one-way ANOVA with Tukey's multiple comparison test (GraphPad
Prism version 4; GraphPad Software, San Diego, CA) and significance accepted when P <
0.05.
Results
PK1 and PKR1 are expressed in third-trimester placenta and pregnant and nonpregnant
myometrium
PK1 mRNA was detected in all placental (n = 16) and myometrial samples (pregnant and
nonpregnant, n = 9 and n = 6, respectively) examined by quantitative RT-PCR. Relative
expression of PK1 mRNA was significantly higher in placenta than pregnant or nonpregnant
myometrium (3.24±0.6 vs. 0.49 ± 0.09 vs. 0.01 ± 0.003, respectively; P < 0.01). There was
no significant difference in relative PKR1 mRNA expression between third-trimester
placenta or pregnant or nonpregnant myometrium (0.85 ± 0.27 vs. 1.18 ± 0.76 vs. 0.29 ±
0.07, respectively; Fig. 1).
PK1 and PKR1 are immunolocalized to various cell types in third-trimester human placenta
PK1 was immunolocalized to the syncytiotrophoblast layer of placental villi (Fig. 2, A and
B) with additional immunostaining present in cytotrophoblasts and the endothelium of
occasional fetal blood vessels (Fig. 2B). Similarly, PKR1 was localized to the
syncytiotrophoblast layer (Fig. 2, C and D) and cytotrophoblast cells. PKR1 was
consistently present in endothelium of fetal blood vessels and was also localized in
macrophages (Hofbauer cells) present in the villous core (Fig. 2D). Immunostaining was
absent from negative control sections (Fig. 2, A and C, insets).
PKR1 colocalizes with cytokeratin, CD31, and CD68 in placenta
Immunofluorescent histochemistry and confocal microscopy were used to characterize the
cell types associated with PKR1 immunoreactivity in third-trimester placenta. PKR1 and
cytokeratin colocalized mainly to syncytiotrophoblast (Fig. 3, A–C). In addition, PKR1 and
cytokeratin colocalized to occasional cytotrophoblast cells with positive staining occurring
on the surface or between cells (Fig. 3, D–F). Some cytotrophoblast cells were positive only
for cytokeratin and did not colocalize with PKR1. PKR1 colocalized with CD31 (blood
vessel marker) in fetal vessels (Fig. 3, G–I) and CD68 (macrophage marker) in placental
macrophages (Fig. 3, J–L). Occasional cells positive for CD3 (T-cell marker; Fig. 3M) and
CD20 (B-cell marker; Fig. 3N) were seen, but they did not colocalize with PKR1.
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PK1 up-regulates placental expression of COX-2 and IL-8
To determine the effect of PK1 on COX-2 and IL-8 expression in third-trimester placenta,
placental explants, preincubated in serum-free medium, were then incubated with 40 nM PK1
for 2, 4, 6, 8, and 24 h. After 4 h incubation with 40 nM PK1, there was a significant fold
increase in COX-2 mRNA expression in placenta compared with vehicle-treated placental
explants (2.75 ± 0.54; Fig. 4A; P < 0.05). IL-8 mRNA expression was significantly
increased at both 2 and 4 h after treatment with 40 nM PK1 (1.96 ± 0.24 at 2 h and 2.03 ±
0.27 at 4 h P < 0.05; Fig. 4C). Incubation of placental explants with 40 nM PK1 for 4 h in the
presence of inhibitors of Gq, cSrc, EGFR, or MEK resulted in a significant fold decrease in
expression of both COX-2 (P < 0.05; Fig. 4B) and IL-8 (P < 0.05; Fig. 4D) relative to
placental tissue treated with 40 nM PK1 alone.
PKR1 induces ERK phosphorylation via cross-talk with EGFR
To confirm the pathways involved in PKR1 signaling in third-trimester placenta, placental
explants were incubated with PK1 for 5, 10, 20, and 30 min and subsequently analyzed for
phosphorylation of cSrc, EGFR, and ERK1/2. There was a significant time-dependent
increase in phosphorylation of ERK1/2 that peaked at 30 min (Fig. 5A; 3.55 ± 0.5-fold
increase compared with vehicle-treated explants). Coincubation of placental explants with
PK1 and inhibitors of Gq, cSrc, EGFR, or MEK caused a significant decrease in ERK1/2
phosphorylation (Fig. 5B; P < 0.05). Treatment of placental explants with 40 nM PK1 also
resulted in an approximately 2-fold increase in phosphorylation of cSrc and EGFR (Fig. 5C).
However, the time to onset of phosphorylation of both proteins was variable between
different placental explant cultures and ranged from 10–30 min.
PKR1 colocalizes with COX-2 and IL-8 in placenta
Immunofluorescent histochemistry and confocal microscopy were used to characterize
colocalization of PKR1 with COX-2 or IL-8 in third-trimester placenta. PKR1 and COX-2
were colocalized in syncytiotrophoblast (Fig. 6, A–C), cytotrophoblast (Fig. 6, D–F) and
macrophages (Fig. 6, G–I). IL-8 and PKR1 were predominately colocalized to fetal vascular
endothelium (Fig. 6, J–L).
Discussion
This study demonstrates that PK1 and PKR1 are highly expressed in third-trimester placenta
with PK1 up-regulating expression of IL-8 and COX-2 potentially via activation of PKR1
and cross-talk with EGFR. The latter finding is supported by double-immunofluorescent
immunohistochemistry studies that show that PKR1 colocalizes with IL-8 and COX-2 in
placenta. Together, these data suggest that PK1 may be a novel paracrine mediator of the
inflammatory response in third-trimester placenta.
The data presented confirm that PK1 is expressed in third-trimester placenta (22, 23) and, in
addition, demonstrate that its receptor PKR1 is also expressed in term placenta. The study
also demonstrates that PK1 is localized to syncytiotrophoblast, cytotrophoblast, and fetal
endothelium. This tissue distribution is similar to that described by Hoffmann et al. during
the first trimester (6) in which expression and localization of PK1 was maximal in
syncytiotrophoblast between 8 and 10 wk gestation. They proposed that PK1 may therefore
have a role in trophoblast differentiation during the critical hypoxic period of placentation.
The colocalization of PKR1 to macrophages demonstrated in this study suggests that PK1/
PKR1 may have an additional novel role as a paracrine modulator of the immune response
in placental macrophages.
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This study also displays PK1 and PKR1 expression in myometrium. PKs were initially
described as novel factors that mediated potent and sustained smooth muscle contractility in
guinea pig ileum (24). However, subsequent studies have yielded conflicting results with
PK1 reported to cause relaxation through a nitric oxide-mediated mechanism in murine
proximal colon (25). This suggests that the specific cellular environment may determine
different intracellular receptor coupling, thereby accounting for the phenotypic difference.
More studies are required to investigate whether PK1 affects human myometrial contractility
during pregnancy.
Previous studies have shown that PK1 signaling couples to Gq in transfected CHO cells (2,
26) and adrenal cortex capillary endothelial cells, resulting in cellular proliferation and
migration in the latter cell type (3). To determine the intracellular signal transduction
pathways activated by PK1 in placenta, chemical inhibitors of Gq, cSrc, EGFR, and MEK
were used. PK1/PKR1 induced rapid sequential phosphorylation of cSrc, transactivation of
EGFR, and phosphorylation of ERK1/2. Furthermore, phosphorylation of cSrc and EGFR in
response to PK1 peaked within the time frame of maximal ERK1/2 phosphorylation. These
data therefore suggest that in placenta, PK1 also signals via Gq coupling and EGFR
transactivation.
Furthermore, we demonstrate that via EGFR transactivation, PK1 induces expression of IL-8
and COX-2 in third-trimester placenta. IL-8 (27) and COX-2 (28), together with
prostaglandins and their receptors, are expressed in the human placenta throughout
pregnancy (29, 30). IL-8 and COX-2 act synergistically to facilitate vascular permeability
and inflammatory cell infiltration and activation (31). Moreover, both IL-8 and COX-2 are
up-regulated in reproductive processes characterized by an inflammation including
chorioamnionitis, preeclampsia, and parturition (32-35). We propose that PK1/PKR1
signaling may provide a common pathway by which an inflammatory response may be
initiated within third-trimester placenta.
The EGF/EGFR loop is an important modulator of trophoblast biology. During the first
trimester, EGFR activation modulates the proliferative, migratory, and invasive potential of
extravillous trophoblast. This effect is both direct via binding of EGF (36) and indirect via
receptor transactivation and subsequent up-regulation of factors including human chorionic
gonadotropin, human placental lactogen (37), matrix metalloproteinase-9, and tissue
inhibitor of metalloproteinase-1 (38). During later pregnancy, the expression pattern of
EGFR is altered in placentae of pregnancies complicated by preeclampsia and intrauterine
growth restriction (39), supporting a role for EGFR in regulating placental biology
throughout pregnancy. It has been previously hypothesized that PK1 may have an important
role in trophoblast differentiation and invasion (11). Demonstration that PK1 signals via
transactivation of EGFR, which is known to have an important role in trophoblast
differentiation, supports this hypothesis and may provide a mechanism by which it may
affect trophoblast biology in the third trimester.
This study further demonstrates that, via transactivation of EGFR, PK1 may be a novel
mediator of the inflammatory response in placenta by up-regulating IL-8 and COX-2
expression. Enhanced production of IL-8 and COX-2 via EGFR-dependent mechanisms has
previously been shown in severe asthma (40) and human colonic aberrant crypt foci (41),
respectively. There is also evidence that EGFR may be up-regulated during inflammation,
with increased expression during labor resulting in enhanced stimulation of prostanoid
production and stimulation of uterine activity (42). Trans-activation of EGFR by PK1 with
subsequent up-regulation of IL-8 and COX-2 may therefore provide a novel mechanism for
initiation of an inflammatory response in placenta.
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Many factors are thought to initiate inflammation. However, a growing body of evidence
supports hypoxia as having a key role in initiating inflammatory reproductive processes (43,
44). PK1 is up-regulated by hypoxia in first-trimester trophoblast, probably via a hypoxia-
inducible factor (HIF1α) binding site in its upstream promoter (6). EGFR (45), IL-8 (46),
and COX-2 (47) are also up-regulated by HIF1α with placental expression increasing in
conditions characterized by hypoxic stress including parturition (32), placental vascular
disease (48), chorioamnionitis (34), and preeclampsia. We postulate that under hypoxic
conditions, the role of PK1 in mediating an inflammatory response might be further
enhanced via HIF-1α-mediated up-regulation in expression of PK1, EGFR, and its
downstream effectors including IL-8 and COX-2. This response might be further augmented
by a paracrine effect of PK1 on macrophages (10).
In conclusion, this study demonstrates a potential novel role for PK1 as a mediator of the
inflammatory response in placenta. Further studies are required to investigate expression and
regulation of PK1 and PKR1 in placenta under normoxic and hypoxic conditions in vitro
and in physiological and pathological situations in vivo including parturition, placental
insufficiency, and preeclampsia.
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Fig. 1.
Relative expression of PK1 and PKR1 in third-trimester human placenta and pregnant (preg)
and nonpregnant (nonpreg) myometrium (myo). Relative expression of PK1 and PKR1
mRNA were determined by real-time quantitative RT-PCR analysis in third-trimester
placenta (n = 16), third-trimester myometrium (n = 9), and nonpregnant myometrium (n =
6). Relative expression of PK1 mRNA was significantly higher in placenta than pregnant or
nonpregnant myometrium. There was no significant difference in relative PKR1 mRNA
expression between third-trimester placenta and pregnant or nonpregnant myometrium. Data
are expressed as mean ± SEM; b is significantly different from a (P < 0.01).
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Fig. 2.
Immunohistochemical localization of PK1 and PKR1 in third-trimester human placenta (n =
8). PK1 was immunolocalized to the syncytiotrophoblast (st) layer of placental villi,
cytotrophoblasts (ct), and endothelium (e) of fetal blood vessels (bv) (A and B). PKR1 was
immunolocalized to macrophages (m) in the villous core, syncytiotrophoblast (st),
cytotrophoblasts (ct), and endothelium (e) (C and D). Immunohistochemistry negatives
(Neg, insets) were incubated with isotype-matched IgG in place of primary antibody and
displayed no immunoreactivity. Scale bars, 50 μM).
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Fig. 3.
Colocalization of PKR1 with cytokeratin, CD31, and CD68 in third-trimester human
placenta (n = 4). PKR1 was colocalized with cytokeratin 18 (trophoblast marker), CD31
(blood vessel marker), CD68 (macrophage marker), CD3 (T-cell marker), and CD 20 (B-cell
marker) by dual-immunofluorescence immunohistochemistry in third-trimester placenta.
PKR1 (red, A and D) and cytokeratin 18 (green, B and E) were colocalized (yellow channel,
merged, C and F) in syncytiotrophoblasts (st) and in some cytotrophoblasts (ct). PKR1 (red,
G) and CD31 (green, H) were colocalized in blood vessel (bv) endothelium within villi
(yellow channel, merged, I). PKR1 (red, J) colocalized with CD68 (green, K) to
macrophages (m, yellow channel, merged, L). PKR1 did not colocalize with CD3 (M,
merged) or CD20 (N, merged). Control sections were incubated with normal IgG from the
same host species and displayed no immunoreactivity (O). Original magnification, ×40.
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Fig. 4.
Relative expression of COX-2 and IL-8 in response to PK1 in third-trimester human
placenta. Third-trimester placental explants were treated for 2, 4, 6, 8, and 24 h in the
presence of vehicle or 40 nM PK1, and COX-2 and IL-8 expression was measured by real-
time RT-PCR (n = 4). To investigate the signaling pathway, placental explants were treated
for 4 h in the presence of vehicle or 40 nM PK1 and chemical inhibitors of Gq (YM254890, 1
μM), EGFR kinase (AG1478, 200 nM), cSrc (PP2, 10 μM), or MEK (PD98059, 50 μM), with
COX-2 and IL-8 expression being measured as before (n = 3). A, There was a significant
fold increase in COX-2 expression at 4 h in placenta treated with 40 nM PK1 compared with
vehicle-treated control (P < 0.05); B, there was a significant fold decrease in COX-2 in
explants treated with PK1 in the presence of chemical inhibitors relative to placenta treated
with PK1 alone (P < 0.05); C and D, similarly, there was a significant fold increase in IL-8
expression at 2 and 4 h in placenta treated with PK1 compared with vehicle-treated control
(P < 0.05; n = 4) (C) with expression being significantly reduced in the presence of chemical
inhibitors (P < 0.05; n = 3) (D). Results are expressed as mean ± SEM; b is significantly
different from a (P < 0.05), and c is not significantly different from a or b.
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Fig. 5.
Phosphorylation of ERK, EGF, and cSrc in response to PK1 in third-trimester human
placenta. Placental explants were incubated with 40 nM PK1 for 5, 10, 20, and 30 min and
subsequently analyzed for phosphorylation of ERK1/2, cSrc, and EGFR (n = 3). A, There
was a time-dependent increase in phosphorylation of ERK1/2 that peaked at 30 min (c is
significantly different from a but not b; P < 0.05). Explants treated for 30 min with vehicle
or 40 nM PK1 in the presence of chemical inhibitors of Gq (YM254890), EGFR kinase
(AG1478), cSrc (PP2), or MEK (PD98059) were then subsequently analyzed for ERK
phosphorylation (n = 7). B, There was a significant decrease in ERK 1/2 phosphorylation in
explants incubated with inhibitors compared with explants treated with PK1 alone (b is
significantly different from a; P < 0.05). Placental explants were stimulated with 40 nM PK1
for 0, 10, 20, and 30 min, and lysates were immunoprecipitated with anti-phosphotyrosine
antibody and then subjected to Western immunoblot analysis using antibodies against cSrc
and EGFR (n = 4). Treatment with 40 nM PK1 resulted in a 2-fold increase in
phosphorylation of Src and EGFR within 20 min of treatment. C, IgG was used to
demonstrate equal sample loading (representative blot). Data are shown as mean ± SEM.
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Fig. 6.
Colocalization of PKR1 with COX-2 and IL-8 in third-trimester human placenta (n = 4).
PKR1 was colocalized with COX-2 and IL-8 by dual immunofluorescence in third-trimester
placenta. PKR1 (red, A, D, and G) and COX-2 (green, B, E, and H) were colocalized in
syncytiotrophoblasts (st), cytotrophoblasts (ct), and macrophages (m) in placenta (yellow,
merged, C, F, and I, respectively). PKR1 (red, J) and IL-8 (green, K) were colocalized to
fetal blood vessels (bv) within villi (yellow channel, L). Inset in B shows negative (Neg)
control (original magnification ×40).
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